Scientists explain binding action of 2 key HIV antibodies; could lead to new vaccine design

Nov 09, 2009

A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

"Our study clearly showed that we've been overlooking a very important component of antibody function," says S. Munir Alam, Ph.D., an associate professor of medicine at Duke University Medical Center and lead author of the paper appearing in the .

Alam, a member of the Duke Human Institute and study senior author Bing Chen, Ph.D., assistant professor of pediatrics, Harvard Medical School and Children's Hospital Boston, studied two potentially powerful against HIV, 2F5 and 4E10. Both of these are rare, broadly neutralizing antibodies, meaning that they can block a number of different strains of the . They accomplish that by binding to the "Achilles heel" of the virus - the so-called outer coat membrane proximal region - a part of the outer protein coating next to the viral membrane that opens up and is exposed to the antibodies for just a few minutes during the process of cell fusion and infection.

But the problem for infection control is that such powerful antibodies are rare in , and current experimental vaccines have been unable to generate such antibodies. In addition, the window of opportunity for such antibodies to act is very narrow.

"The target region on the virus is only open for a few minutes - maybe 15 minutes or less," says Alam. "Unless the antibody is very close by and ready to home in on it, it won't work. That means our goal has to be the creation of a vaccine that can induce a whole lot more of these antibodies and have them ready to go at the earliest moment of infection."

"Fortunately, our study gave us new information that will help us accomplish this goal," says Chen.

The 2F5 and 4E10 antibodies have unusually long, loopy protein segments that are hydrophobic, meaning that they are attracted to lipids. The researchers found that successful docking of the antibody to the outer coat membrane region required antibody attachment to HIV's membrane, which contains lipid.

"This two-step mechanism, not previously appreciated, might extend to antibodies that protect against other viruses," says co-author Stephen Harrison, Ph.D., of Harvard Medical School, Children's Hospital Boston, and the Howard Hughes Medical Institute.

The research team is already working on designing a vaccine that incorporates a lipid component. "The demonstration of the role of virion lipid reactivity in the overall function of these neutralizing antibodies has provided key insights into what the immune system may need to see to make such antibodies", says co-author and Vaccine Institute Director Barton Haynes. "New vaccine designs trials based on these observations are now ongoing in animals."

Source: Duke University Medical Center (news : web)

Explore further: Research milestone in CCHF virus could help identify new treatments

add to favorites email to friend print save as pdf

Related Stories

Scientists Find Rare, Potent Antibody to HIV-1

Feb 23, 2009

(PhysOrg.com) -- Scientists at Duke University Medical Center have for the first time isolated an important antibody in human serum that could potentially play a key role in the design of an AIDS vaccine. The research appears ...

Uncovering the Achilles' heel of the HIV-1 envelope

Jan 11, 2008

New structural details illustrate how a promising class of antibodies may block human immunodeficiency virus (HIV)-1 infection and reveal valuable clues for design of an effective HIV-1 vaccine.

Recommended for you

A new way to prevent the spread of devastating diseases

11 hours ago

For decades, researchers have tried to develop broadly effective vaccines to prevent the spread of illnesses such as HIV, malaria, and tuberculosis. While limited progress has been made along these lines, ...

New molecule allows for increase in stem cell transplants

12 hours ago

Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the fi ...

Team explores STXBP5 gene and its role in blood clotting

15 hours ago

Two independent groups of researchers led by Sidney (Wally) Whiteheart, PhD, of the University of Kentucky, and Charles Lowenstein, MD, of the University of Rochester, have published important studies exploring the role that ...

User comments : 0